CD274 and hepatocellular carcinoma: The incidence rate of liver cancer is very close to its mortality rate due to very poor prognosis in all regions around the world.28 PD-L1 inhibitor atezolizumab in combo with bevacizumab has become the new standard-of-care (SoC) first-line treatment for advanced HCC after demonstrating improvement in both 12 months overall survival (OS) and progression-free survival (PFS) compared to the previous SoC Nexavar,29 but there's still a huge unmet medical need for HCC patients.